Table-1.
Patient characteristics at blast phase CML (CML-BP)
| Characteristic | No. (%), or Median [Range] |
|---|---|
| N | 477 |
| Age at BP, years [range]* | 53 [16–84] |
| Gender (Male/Female) | 305 (64)/172 (36) |
| Ethnicity (Caucasian/Others) | 312 (65)/165 (35) |
| Hemoglobin [g/dL]* | 10 (0–16) |
| WBC (K/μL)* | 19 (0–768) |
| Platelet (K/μL)* | 77 (0–2750) |
| Peripheral blood blast % | 21 (0–145) |
| Bone Marrow blast %* | 40 (0–99) |
| Serum LDH (IU/L)* | 1242 (0–21874) |
| Serum Uric Acid (mg/dL) | 5.6 (0.7–20) |
| Myeloid/Lymphoid immunophenotype | 308 (67)/128 (28) |
| Prior TKI (Yes/No) | 343 (72)/134 (28) |
| Transcript Type | |
| e13a2 | 182 (41) |
| e14a2 | 170 (39) |
| e13a2 +e14a2 | 74 (17) |
| e1a2 | 14 (3) |
| Extramedullary disease | 128 (27) |
| Isolated extramedullary disease | 50 (39) |
| CNS involvement at any point (Yes/No) | 50 (13)/327 (87) |
| SCT after BP (Yes/No) | 104 (22)/373 (78) |
| Characteristic | No. (%), or Median [Range] |
| Patients with ABL mutation testing | 187 (39) |
| T315I | 28 (15) |
| E255K | 15 (8) |
| F317L | 12 (6) |
| Miscellaneous# | 39 (21) |
| Negative | 93 (50) |
| Initial Treatment Type** | 426 (89) |
| TKI Alone | 149 (35) |
| TKI with chemotherapy | 195 (46) |
| Others Non-TKI therapies | 82 (19) |
| Type of TKI’s used | |
| Imatinib | 189 (55) |
| Dasatinib | 110 (32) |
| Nilotinib | 26 (7) |
| Bosutinib | 5 (1) |
| Ponatinib | 15 (4) |
| CML phase at initial diagnosis | |
| Chronic Phase (CP) | 381 (80) |
| Accelerated phase (AP) | 25 (5) |
| Blast phase (BP) | 71 (15) |
| Time from initial diagnosis to BP (months) | 26 [0–298] |
| CP to BP | 381 (80), 41 [0.7–298] |
| AP to BP | 25 (5), 14 [0.4–160] |
| Median follow-up (months) | 11.5 (0–195) |
| Last follow up status (Alive/Died) | 95 (20)/382 (80) |
*
Optimal cut off values identified by CART analysis for different variables were – age (<58 years vs ≥ 58 years), hemoglobin (<13 gm/dL years vs ≥ 13 gm/dL), white blood cell count (WBP) none identified, platelet count 102 K/μL, bone marrow blast % (<5% vs ≥ 5%), serum lactate dehydrogenase (LDH) (<1227 IU/L vs ≥ 1227 IU/L),
#
* ABL mutations (n) – Y253H (8), G250E (4), Q252H (3), E255V (3), M351T (3), V299L (2), F311L (2), H396R (2), other mutations (12, 1 each),
**
Among those patients who had initial treatment information available